| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1b49b135f099e96a0e4cab2427a48ae8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c4afb8b01aa8de7e0b24a86713b23a18 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H5-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-224
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-232
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7036 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H5-06 |
| filingDate |
2018-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_679667301decdc519c23a87dd490b250
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_055499687919bf2053bb539ea30aa9f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c7d5f69675c65942edb9b40deb27c19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8be34bedbc96860dd8b53a5e77b08b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_549e4ca13c3df631f5cc2c8d27910eec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dda1277687667cdeeb85e04ddd6c3d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75b0a51071b51aa3b8e3e4210bdeeb6e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74bc0d14359d3df1c6987d95f94ddeff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ff4fdb306706a1dd10e7dba9335aa3b |
| publicationDate |
2020-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020062793-A1 |
| titleOfInvention |
Apramycin derivatives |
| abstract |
The invention relates to derivatives of apramycin-based aminoglycoside antibacterial drugs modified in positions C5 and/or C6 and O5 and/or O6. The modifications impart favourable properties regarding increased selectivity and retention of activity in the presence of resistance determinants of the AAC(3) class. The invention further relates to said compounds for use in the therapy of bacterial infection by systemic administration, especially in instances where the infection is caused by a pathogen comprising a resistance determinant of the AAC(3) class, in particular AAC(3)-IV. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022020295-A1 |
| priorityDate |
2017-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |